What is the success rate of ibogaine treatment?

Evidence level: C Emerging evidence — observational studies and case series, no randomised controlled trials yet. We say so wherever it matters.

In the best available published data, 61% of patients were abstinent following ibogaine treatment, with a median of 5.5 months of abstinence after a single session and 8.4 months among those treated more than once.

Those are real numbers from a peer-reviewed study — and on their own they will mislead you, in both directions. They describe 75 screened patients in one hospital programme who also completed psychotherapy, with a specific set of dependencies. They are not a prediction for any individual, and they are certainly not the 90%-plus figures some clinics advertise.

This page explains what “success” actually means in addiction treatment, what the evidence supports, and — more usefully — what determines whether someone ends up in the group that stays well.

What "success" even means

Before any percentage means anything, three questions have to be answered — and clinics quoting success rates rarely answer them.

Success at what? Complete abstinence is one definition. Substantially reduced use is another. Some studies measure withdrawal completion, which says nothing about what happened next.

Measured when? Abstinence at one month, six months and two years are entirely different achievements. A “95% success rate” measured at discharge is meaningless — almost everyone is abstinent when they leave a clinic.

Among whom? Outcomes in a screened, motivated cohort who completed weeks of preparation are not the outcomes of everyone who walks in.

There is also a strong argument that abstinence alone is the wrong measure. Current recommendations in addiction research call for secondary outcomes as well — craving, relationships, quality of life, and self-efficacy — on the reasoning that someone who has stopped using but whose life has not improved has not really been treated. The 2016 qualitative study of this Brazilian programme found improvement across all of those measures.

Ibogaine research in detail →

What the published data shows

The clearest figures come from the 2014 retrospective study of 75 patients treated for alcohol, cannabis, cocaine and crack dependence — 72% of them polydrug users — in a hospital programme in Brazil.

  • 61% abstinent at follow-up
  • Median 5.5 months of abstinence after one treatment
  • Median 8.4 months among those treated more than once
  • The difference between single and multiple treatment was statistically significant (p < 0.001)
  • Both groups sustained longer abstinence than before their first ibogaine session (p < 0.001)

Two caveats carry real weight. There was no control group, so the study cannot separate ibogaine’s contribution from that of the psychotherapy, the screening or the patients’ own motivation. And this cohort was non-opioid — the figures should not be applied to opioid dependence, where ibogaine is most commonly used but least formally studied.

Ibogaine research and evidence →

For context — what conventional treatment achieves

These figures mean little without a baseline, and the baseline is sobering.

According to the National Institute on Drug Abuse, 40–60% of people treated for addiction relapse. That is not a failure of any particular programme; it reflects that addiction behaves like other chronic, relapsing conditions.

This context matters in both directions. It explains why interest in ibogaine exists at all — the standard of care leaves a large group of people without a durable result, which is exactly the group that ends up researching alternatives. And it tempers expectations: no treatment in this field, ibogaine included, produces reliable one-shot cures.

What actually determines the outcome

This is the part worth reading closely, because it is the part you can influence.

Psychotherapy is not optional. In the programme that produced these results, ibogaine is regarded as a facilitator of psychotherapy rather than as the treatment itself — roughly four sessions before and four after. Patients who do not want to engage in psychological work are not accepted for treatment at all. The programme treats this work as what sustains the result.

Repeat treatment improved outcomes. Median abstinence rose from 5.5 to 8.4 months among patients treated more than once — a statistically significant difference, and a strong argument against framing ibogaine as a single event.

Preparation predicts a lot. The published protocol required 30 to 60 days of verified abstinence beforehand. That requirement is partly pharmacological safety — and partly a filter: completing it demonstrates the motivation that the treatment then builds on.

Aftercare covers the risky period. The first weeks and months after treatment carry the highest relapse risk, and structured support through them is what converts a good session into a durable outcome.

Family support was an inclusion criterion in the published protocol — a reminder that recovery is not carried out in isolation.

The pattern is consistent: outcomes track the structure around the session far more than the session itself.

What happens after ibogaine treatment →

What ibogaine does not do

Three limits, stated plainly.

It does not cure addiction. It interrupts withdrawal and reduces craving, which removes the obstacles to recovery — it does not perform the recovery.

It does not remove the reasons someone used. The trauma, circumstances and patterns underneath dependence remain, and they are what the psychotherapy addresses.

It does not make relapse impossible. The craving may go away, but a patient may still use — because craving was never the whole reason. Something has to take the place it occupied.

Any provider promising a cure is describing a product that does not exist.

Success-rate claims and how to test them

If a clinic quotes you a figure, four questions establish whether it means anything:

  1. Is it published, and where? Internal statistics are not evidence. Ask for the citation.
  2. Measured how long after treatment? If the answer is “at discharge”, the number is worthless.
  3. How was success defined — abstinence, or reduced use?
  4. How many patients, with which dependencies, and how many were lost to follow-up? Patients who disappear from a study are rarely the ones doing well.

Two red flags are close to definitive. A rate above 90% is not consistent with anything in the published literature on addiction treatment of any kind. And a clinic that has no idea what proportion of its patients relapse is telling you it does not follow them up.

How to choose an ibogaine clinic →

A realistic expectation

Based on what is actually documented, a reasonable expectation looks roughly like this.

Withdrawal is likely to be interrupted — this is ibogaine’s most consistently observed effect. Craving is likely to be substantially reduced, in many cases for months rather than days. Whether that becomes lasting recovery depends heavily on what surrounds it: psychotherapy, aftercare, environment and support.

Some people achieve years of abstinence from a single treatment. Some benefit substantially and later need repeat treatment. Some relapse. Published data cannot tell you in advance which group you will be in, and any clinic claiming otherwise is guessing with confidence.

What can be said is that the people who do best are consistently those who treated ibogaine as the beginning of a process rather than the end of a problem.

Getting an honest assessment

We are not a clinic, and we will not inflate a number. We regularly tell people that their expectations, or their case, do not fit what this treatment realistically offers.

If you want a straight answer about likely outcomes in your situation, including the factors that would improve or undermine them, ask us.

Get an honest assessment of your case

Free and confidential. Our team reviews your request and replies within 24 hours.

Sources

  1. Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. Journal of Psychopharmacology. 2014;28(11):993–1000. doi:10.1177/0269881114552713
  2. Schenberg EE, de Castro Comis MA, Alexandre JFM, Chaves BDR, Tófoli LF, da Silveira DX. Treating drug dependence with the aid of ibogaine: a qualitative study. Journal of Psychedelic Studies. 2017;1(1):10–19 (published online 2016). doi:10.1556/2054.01.2016.002

Frequently asked questions

01. What is the success rate of ibogaine treatment?
In the main published study, 61% of 75 patients were abstinent at follow-up, with median abstinence of 5.5 months after one treatment and 8.4 months after multiple.
02. Does ibogaine actually work?
It reliably interrupts withdrawal and reduces craving. Whether that becomes lasting recovery depends largely on psychotherapy and aftercare.
03. Does ibogaine cure addiction?
No. It removes withdrawal and craving, creating a window for recovery work — it does not complete that work.
04. How long does the effect of ibogaine last?
Published medians were 5.5 months of abstinence after one treatment and 8.4 months among those treated more than once.
05. What is the relapse rate after ibogaine?
In the published cohort, 39% were not abstinent at follow-up. For context, NIDA reports 40–60% relapse across addiction treatment generally.
06. Do multiple ibogaine treatments work better?
In the published study patients treated more than once sustained significantly longer abstinence — 8.4 months versus 5.5.
07. Are 90% ibogaine success rates real?
No figure that high is consistent with the published literature on addiction treatment. Treat such claims as a warning sign.

This article summarises published outcomes for information only and is not medical advice or a prediction of individual results. Ibogaine is not an approved medicine in any country.

Get a free, confidential assessment

Our consultation is free for you. Medical decisions are made by the clinic's doctors.